This author interview is by Mr Abdulqadir J. Nashwan, of National Center for Cancer Care and Research, Qatar. Mr Nashwan 's full paper, Cytomegalovirus induced Hemorrhagic Colitis in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy, is available for download in Clinical Medicine Insights: Case Reports.

Please summarise for readers the content of your article
The study reports a case of a 39-year-old Ethiopian female patient who received Dasatinib (tyrosine kinase inhibitor that inhibits the "Philadelphia chromosome" in patients with Chronic Myeloid Leukemia (CML)) and the patient developed hemorrhagic colitis due to cytomegalovirus (CMV) infection of the colon.

How did you come to be involved in your area of study?
This case was followed by Dr. Mohamed Yassin (Hematology Consultant) and I have participated by searching the available literature and reviewing the scientific content.

What was previously known about the topic of your article?
Few studies have reported hemorrhagic colitis induced by Dasatinib as a rare adverse effect and in this case Dasatinib was used as an upfront therapy (usually Imatinib is use as a first-line therapy for CML patients).

How has your work in this area advanced understanding of the topic?
This will shed the light on the complications of Dasatinib and will contribute to early detection and management.

What do you regard as being the most important aspect of the results reported in the article?
This study will raise the awareness among healthcare providers to look for preventive measures for CML patients on Dasatinib therapy.

 

share on